{
  "id": "54e071e11388e8454a00000d",
  "type": "list",
  "question": "Which agents are included in the FLAMSA chemotherapy regimen?",
  "ideal_answer": "Fludarabine, cytarabine and amsacrine are included in the FLAMSA chemotherapy regimen.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/18176613",
    "http://www.ncbi.nlm.nih.gov/pubmed/23728608",
    "http://www.ncbi.nlm.nih.gov/pubmed/21963618",
    "http://www.ncbi.nlm.nih.gov/pubmed/21358688",
    "http://www.ncbi.nlm.nih.gov/pubmed/19430496",
    "http://www.ncbi.nlm.nih.gov/pubmed/23652585",
    "http://www.ncbi.nlm.nih.gov/pubmed/22983588"
  ],
  "snippets": [
    {
      "text": "After 3 days of rest, RIC was carried out, consisting of 4 Gy total body irradiation, antithymocyte globulin (ATG-Fresenius), and cyclophosphamide (fludarabine, amsacrine, and cytarabine (FLAMSA)-RIC protocol).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728608",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We report a retrospective single center analysis of aplasia-inducing chemotherapy using fludarabine, cytarabine, and amsacrine (FLAMSA) followed by reduced-intensity conditioning (RIC) for allogeneic hematopoietic cell transplantation (HCT) in 62 consecutive primary refractory or relapsed AML patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23652585",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A sequential regimen of cytoreductive chemotherapy (fludarabine, high-dose AraC, amsacrine) followed by reduced intensity conditioning (FLAMSA-RIC), was uniformly used for conditioning.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22983588",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Between November 2003 and June 2010, 30 patients (20 high-risk MDS, 10 sAML) received fludarabine (4 \u00d7 30 mg/m(2)), amsacrine (4 \u00d7 100 mg/m(2)), and Ara-C (4 \u00d7 2 g/m(2), FLAMSA). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21963618",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The preparative regimen consisted of fludarabine, Ara-C and amsacrine (FLAMSA) chemotherapy, followed by reduced intensity conditioning (RIC) 3 days later. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21358688",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Fifteen patients received fludarabine 30 mg/m(2), cytarabine 2000 mg/m(2), amsacrine 100 mg/m(2) on days -10, -9, -8 and -7, anti-thymocyte globulin (ATG-Fresenius) 20 mg/kg body weight on days -6, -5 and -4 and fractionated total body irradiation 2 x 2 Gy on days -3, -2 and -1 (FLAMSA-ATG-TBI) before allogeneic hematopoietic stem cell transplantation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19430496",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The goal of this analysis was to define the role of the moderate-intensity fludarabin Ara-C amsacrin (FLAMSA)-reduced intensity conditioning (RIC) regimen for patients with high-risk AML undergoing allogeneic SCT (alloSCT) in first CR1. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18176613",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The goal of this analysis was to define the role of the moderate-intensity fludarabin Ara-C amsacrin (FLAMSA)-reduced intensity conditioning (RIC) regimen for patients with high-risk AML undergoing allogeneic SCT (alloSCT) in first CR1",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18176613",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The preparative regimen consisted of fludarabine, Ara-C and amsacrine (FLAMSA) chemotherapy, followed by reduced intensity conditioning (RIC) 3 days later",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21358688",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A sequential regimen of cytoreductive chemotherapy (fludarabine, high-dose AraC, amsacrine) followed by reduced intensity conditioning (FLAMSA-RIC), was uniformly used for conditioning",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22983588",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A sequential regimen of cytoreductive chemotherapy (fludarabine, high-dose AraC, amsacrine) followed by reduced intensity conditioning (FLAMSA-RIC), was uniformly used for conditioning",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22983588",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We report a retrospective single center analysis of aplasia-inducing chemotherapy using fludarabine, cytarabine, and amsacrine (FLAMSA) followed by reduced-intensity conditioning (RIC) for allogeneic hematopoietic cell transplantation (HCT) in 62 consecutive primary refractory or relapsed AML patients",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23652585",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The preparative regimen consisted of fludarabine, Ara-C and amsacrine (FLAMSA) chemotherapy, followed by reduced intensity conditioning (RIC) 3 days later",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21358688",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "fludarabine, cytarabine, amsacrine"
}